Summary slide.png (112.84 kB)

Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19

figure

posted on 2020-08-10, 08:21 authored by Joseph Meletiadis, Sotirios Tsiodras, Panagiotis Tsirigotis

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s40121-020-00326-1

Usage metrics

Read the peer-reviewed publication

Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19

Infectious Diseases and Therapy

Keywords

COVID-19 Cytokine storm IL6 blocking JAK-STAT inhibitors Ruxolitinib Sarilumab Severe respiratory syndrome Siltuximab Tocilizumab

Licence

CC BY-NC 4.0

Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports